PT Kalbe Genexine Biologics on Indonesia biologics landscape

Emily Event News Leave a Comment

As you know, PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and headquartered in Jakarta. It is the largest, publicly listed pharmaceuticals company in Southeast Asia with over US$6 billion in market capitalization and revenues of over IDR 7 trillion (2016). Partnering with Genexine, Inc (KOSDAQ, 095700), another listed company of 20 years history, specialising in clinical stage biotechnology with a focus on the development and commercialization of innovative immuno-therapeutics and next generation novel long acting biologics, PT Kalbe Genexine Biologics is established to promote innovative R&D in Indonesia and South East Asia market.

We are excited to have confirmed the participation of Ms Yuliana Indriati, President Director of PT Kalbe Genexine Biologics to speak at Phar-East 2018 in Singapore on 1-2 March. Prior to the conference, we spoke with Yuliana to give you a preview on what you can expect to learn from her at the conference.


Q: In your opinion, what is the most challenging aspect of operating a pharma company in Indonesia?

Yuliana: The perception of Indonesian people that the price of drugs is expensive  because of a lack of capability in producing drugs with high technology such as biotechnology, and the fact that more than 90% of raw materials are imported.

The government is supporting investment in pharmaceutical industry to increase capacity and capability of producing raw material and product with high technology. This will reducing reliance on importing raw materials and it will increase exchange reserves and export competitiveness


Q: What are you most excited about in the joint venture with Genexine?

Yuliana: PT Kalbe Genexine Biologics is joint venture company between Kalbe and Genexine, Korea.This company is the first company in Indonesia for Research and development patented innovative biologics drugs. This company will support the government on  capability improvement in clinical trial and production with high technology such as biotech through technology transfer from Korea to Indonesia


Q: What is Kalbe’s latest initiative to support Indonesia’s pharma industry?

Yuliana: PT Kalbio Global Medika is a subsidiary of Kalbe, located in Cikarang, Indonesia, with an advanced technology facility for producing biologics products  (bio-betters and biosimilar) to international standards. These drugs are not only for supplying locally but also export to ASEAN, Australia and the Middle East.

Through PT Kalbe Genexine Biologics and PT Kalbio Global Medika, we will encourage implementation of biopharmaceutical R&D within the framework of self reliance of the pharmaceutical industry.  It will support producing patented innovative biologics products and increase products for export.


Q: Where do you see the future of Indonesia’s pharma industry in the next 5 years?

Yuliana: I believe we will see more applied research in drug development in order to become a superior and competitive player in the pharmaceuticals industry.


Q: Who would you like to meet at Phar-East 2018?

Yuliana: We would like to meet companies which are interested to explore business partnership in co-development area.


Yuliana is one of over 50 early confirmed speakers at Phar-East 2018. Visit our website for more information:

About Phar-East 2018
From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has attracted close to 20,000 attendees over the last 10 years. Established as a true one-stop shop for all things biopharma, our 2018 program is rebranded into Phar East 2018 to explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, and more without restricting itself on the type and nature of therapeutic products. Visit our website for more information:

Leave a Reply

Your email address will not be published. Required fields are marked *